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ABSTRACT
Background. To evaluate outcomes of surgical treatment
in patients with hepatic metastases from renal-cell carci-
noma in the Netherlands, and to identify prognostic factors
for survival after resection. Renal-cell carcinoma has an
incidence of 2,000 new patients in the Netherlands each
year (12.5/100,000 inhabitants). According to literature,
half of these patients ultimately develop distant metastases
with 20% involvement of the liver. Resection of renal-cell
carcinoma liver metastases (RCCLM) is performed in only
a minority of patients. Hence, little is known about out-
come of resectable RCCLM.
Methods. Patients were retrieved from local databases of
theNetherlands Task Force for Liver Surgery (14 centers)
and from the Dutch collective pathology database. Survival
and prognostic factors were determined by Kaplan–Meier
analysis and log rank test.
Results. Thirty-three patients were identified who under-
went resection (n = 29) or local ablation (n = 4) of
RCCLM in the Netherlands between 1990 and 2008. These
patients comprise 0.5% to 1% of the total population of
patients diagnosed with RCCLM in that period. There was
no operative mortality. The overall survival at 1, 3, and
5 years was 79, 47, and 43%, respectively. Metachronous
metastases (n = 23, P = 0.03) and radical resection
(n = 19, P \ 0.001) were statistically significant prog-
nosticators of overall survival. Size \ 50 mm (n = 18,
P = 0,54), solitary metastases (n = 19, P = 0.93), and
presence of extrahepatic metastases (n = 11, P = 0.28)
did not have a statistically significant impact on survival.
Conclusions. The favorable 5-year survival rate of 43%
without operative mortality as found in this nationwide
study indicates that selected patients with RCCLM can
benefit from surgical treatment.
In the Netherlands, with a population of 16 millions,
2000 people are diagnosed with renal-cell carcinoma
(RCC) each year with a corresponding incidence of 12.5
per 100,000 inhabitants.1 At presentation, 25 to 30% of
patients with RCC have distant metastases, and another
third develop systemic recurrence after primary tumor
resection.2 Prognosis is poor in patients with metastatic
RCC, with 5-year survival ranging from 5 to 10%.3 Surgery
is still the only curative treatment, while RCC is only little
affected by radiotherapy or chemotherapy.4 Recently,
molecularly targeted therapy has become available for
advanced RCC and showed overall survival benefit in large
multicenter trials.5,6
In addition to the role of surgery in primary therapy,
patients with distant metastases of RCC that are solitary or
restricted to one organ are also candidates for surgi-
cal treatment. Outcomes of surgery for metastatic RCC
have most thoroughly been investigated for pulmonary
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localizations because the lungs are a preferential metastatic
site.7 The liver is less often involved and infrequently is the
only site of metastatic RCC.8 Development of hepatic
metastases is generally considered a poor prognostic factor
and is frequently a predictor of more widespread disease.9
This is why such patients are only incidentally referred for
liver resection, and consequently, there is little available
literature on this topic. Patients with RCC liver metastases
(RCCLM) are often pooled in series with hepatic metas-
tases that are not of colorectal or neuroendocrine origin.
This group includes liver metastases from genitourinary
malignancies, sarcomas, breast cancer, melanoma, and
other primary tumors. Tumor biology and clinical behavior
vary greatly among these different malignancies.
The objective of this study was to determine population
characteristics, survival, and prognostic factors in patients
with RCCLM who underwent local treatment, either by
surgery or ablative techniques, in the Netherlands.
MATERIALS AND METHODS
Patients
To identify a complete cohort of patients with RCCLM
who had been surgically treated in the Netherlands, a
search in the national histopathology database, PALGA,
was performed.10 PALGA (Pathologisch Anatomisch
Landelijk Geautomatiseerd Archief; Pathological Anatomy
National Automated Archive) is a nationwide network and
archive that has been set up in the Netherlands to facilitate
the optimal use of histopathology and cytopathology data.
PALGA has been available since 1971, and all 64 histo-
pathology and cytopathology laboratories in the
Netherlands contribute to it. It currently contains approxi-
mately 42 million excerpts from nearly 10 million
patients.10
This study was conducted under the direction of the
Netherlands Task Force for Liver Surgery. All members
were sent a letter that asked them to check their local
databases for surgically treated patients with RCCLM. In
addition, patient information obtained by the search in
PALGA was provided to aid in this process. A specific
questionnaire designed to acquire a variety of patient
characteristics concerning primary tumor, metastases,
treatment, and outcome was attached to this letter. One of
the investigators (A.T.R.) visited some of the hospitals to
examine and collect the data. Survival data were obtained
from the local hospitals and were updated if necessary by
contacting primary care physicians.
Patients with direct ingrowth of the primary tumor in the
liver or ingrowth of peritoneal metastases in the liver were
excluded from this analysis because of probable different
tumor biology and patient survival. For the same reason,
patients with nephroblastoma as primary tumor were
excluded.9
A total of 37 patients with RCCLM were identified by
the described search strategy. Data from four of these
patients could not be retrieved as a result of unavailability
of the patients’ records in the hospitals concerned. This was
likely the result of the long time period between treatment
and data retrieval (up to 19 years). This resulted in a study
population of 33 patients treated in a 19-year period
between 1990 and 2008. Population characteristics are
displayed inTable 1. Data were obtained from a total of 14
hospitals, including 7 university hospitals and 7 referring
hospitals.
Statistical Analysis
Overall and disease-free survival were determined
according to the Kaplan–Meier method. Potential prog-
nosticators of overall survival were evaluated by univariate
analysis by the log rank test. The univariate tested variables
were chosen on the basis of reported prognostic factors in
the literature on metastatic RCC and colorectal liver
metastases: patient sex and age, site of primary tumor,
characteristics of RCCLM (number, size, metachronous or
synchronous, and disease-free interval), presence of
extrahepatic disease, and completeness of resection. A
multivariate analysis was not feasible in this study as a
result of the small sample size. P values of \ 0.05 were
considered statistically significant. The data were analyzed
with SPSS software, version 16.0 (SPSS, Chicago, IL).
RESULTS
Population Characteristics
Histopathology of the primary tumor could be retrieved
in 28 patients (84%), and showed clear-cell carcinoma in
most patients (63%). Most RCCLM were metachronous
(70%), with a median interval from nephrectomy of 50
(range 7–360) months. RCCLM were multiple in 14
patients (43%), with an upper limit of 19. There was evi-
dence of extrahepatic disease in 11 patients (33%). These
metastases were surgically treated with curative intent
before liver resection, or were synchronously discovered at
laparotomy and subsequently resected. The extrahepatic
metastases included metastases to vagina, omentum, bile
duct, diaphragm, adrenal gland, gallbladder, and lung. The
patient with metastases to the bile duct was previously
described in the literature.11 Twelve patients received
additional systemic treatment including chemotherapy,
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immunotherapy (interferon and interleukin-2), and molec-
ularly targeted therapy (sunitinib and sorafenib).
Operative Data
The surgical treatment performed in these patients
included 8 metastasectomies (24%), 10 segmentectomies
(30%), 4 left hemihepatectomies (12%), 6 right hemihep-
atectomies (18%), 1 extended right hemihepatectomy, and
8 radiofrequency ablations (RFA). RFA was performed in
addition to resection in 4 patients and was the only
treatment modality in another 4 patients. All RFA proce-
dures were performed during laparotomy. Resection
margin was tumor negative in 19 (76%) of 25 patients who
underwent resection, as defined by removal of all macro-
scopically detectable disease and microscopically clear
resection margins. Patients who underwent RFA as solitary
treatment or in combination with resection were excluded
from this analysis. There was no operative mortality, and
postoperative complications developed in 6 patients (18%).
These were classified as major complication (Dindo-Cla-
vien grade IV) in 2 patients (6%).12 This postoperative
morbidity consisted of lung embolism, atrial fibrillation,
intra-abdominal hemorrhage, reversible liver failure,
pleural fluid, and intra-abdominal abscess. Relaparotomy
was only required in the patient who had active postoper-
ative bleeding.
Survival
Complete survival data could be retrieved from all
patients. At the end of the study, 17 patients (52%) had
died. Of the 16 patients (48%) alive, 11 had evidence of
recurrent disease, either hepatic or extrahepatic. The time
to recurrence ranged from 1 to 54 months, with a median
of 10 months. The 1-, 3-, and 5-year disease-free survival
rates were 49, 18, and 11%, respectively (Fig. 1). None of
the patients with recurrent hepatic metastases underwent
repeat liver resection. One patient was diagnosed with
metastases to the lungs after 33 months. He survived two
consecutive metastasectomies of the lungs, and is still alive
after 212 months. Median survival of patients with recur-
rent disease was 23 (range 3–212) months.
TABLE 1 Population characteristics of 33 patients who underwent
surgical or local ablative resection of renal-cell carcinoma liver
metastases
Factor Valuea
Sex
Male 16 (48)
Female 17 (52)
Age (y), median (range) 61 (20–77)
Histology
Clear cell 21 (64)
Chromophobe 3 (9)
Papillary 3 (9)
Other/unknown 6 (18)
Metastases
Time
Synchronous 10 (30)
Metachronous (7–360 mo) 23 (70)
Symptomatic
Yes 9 (45)
No 11 (55)
Size
B50 mm 18 (60)
[50 mm 12 (40)
Number
Solitary 19 (58)
Multiple (1–19) 14 (42)
Localization
Left liver lobe 10 (32)
Right liver lobe 20 (62)
Bilateral lobes 2 (6)
Extrahepatic disease
Yes 11 (33)
No 22 (67)
(Neo)adjuvant therapy
Immunotherapy 7 (21)
Chemotherapy 3 (9)
Molecularly targeted therapy 3 (9)
a Values are expressed as n (%) unless otherwise indicated. Missing
numbers are a result of unknown data
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FIG. 1 Overall survival and disease-free survival after surgical
treatment in patients who underwent resection of renal-cell carcinoma
liver metastases
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Overall 1-, 3-, and 5-year survival rates were 78, 47, and
43%, respectively (Fig. 1). The median overall survival
was 33 (4–224) months.
Univariate Analysis of Prognostic Factors
In the univariate analysis, two factors showed statisti-
cally significant influence on overall survival (Table 2).
None of the patients with an incomplete resection (R1 or
R2) survived longer than 23 months, in contrast to patients
with a complete resection (R0), who had a median survival
of 37 months (P \ 0.001), as shown in Fig. 2. Patients
with synchronous metastases had a statistically signifi-
cantly (P = 0.03) shorter survival than patients with
metachronous metastases (Fig. 3). This effect slightly
diminished when we compared the median overall survival
of patients with a disease-free interval of less than
24 months and those with an interval between primary
tumor and liver metastases of more than 24 months; the
effect was not statistically significant (P = 0.051). Because
of the heterogeneity of the adjuvant therapy, this was not
analyzed as a prognostic factor. Age and sex of the patient
(B60 vs.[60 years), site of the primary tumor, number of
liver metastases, or size of the largest metastasis had no
TABLE 2 Univariate analysis of potential prognostic factors for
overall survival in patients who underwent surgical or local ablative
resection of renal-cell carcinoma liver metastases
Prognostic factor No. of
patients
Median survival
(months)
P value
Age 0.37
B60 years 16 27
[60 years 17 33
Sex 0.38
Male 16 23
Female 17 33
Primary tumor sidea 0.95
Left 14 27
Right 17 [33
Liver metastases
Timing 0.03
Synchronous 10 18
Metachronous 23 [37
Disease-free interval 0.051
B24 months 17 22
[24 months 16 [37
Size of largest
metastasisa
0.54
B50 mm 18 [33
[50 mm 12 24
Number of metastases 0.93
Solitary 19 27
Multiple 14 [33
Extrahepatic disease 0.28
Present 11 27
Absent 22 [37
Resection margin B0.001
Radical resection
(R0)
19a 37
Irradical resection
(R1/R2)
6 9
Data from patients who underwent radiofrequency ablation were not
analyzed
a Data were not available for all patients
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FIG. 2 Overall survival according to resection margins (P \ 0.001).
Patient who underwent radiofrequency ablation were excluded from
this analysis
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FIG. 3 Overall survival according to the timing of resection of renal-
cell carcinoma liver metastases (P = 0.03)
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statistically significant influence on overall survival
(Table 2).
DISCUSSION
Patients with RCCLM generally have a particularly poor
prognosis, which is even worse than patients with RCC
metastases to other organs, such as lungs and bone.13 In the
series of Suppiah et al., the median survival of 186
untreated patients with hepatic RCC metastases was only
7.8 months.13 However, the present population-based study
demonstrates that a selected subgroup of patients with
RCCLM can be offered the possibility of long-term sur-
vival by surgical intervention, either resection or local
ablation. Five-year survival of 43% as found in the present
study is substantially better than the approximately 10%
survival after 1 year reported in the whole group of patients
with RCCLM.14,15
Data regarding the efficacy of surgical treatment of
RCCLM are rarely reported. In a survival analysis based on
15 reports by Aloia et al., 2-year survival was 40%.9
Besides this review including 64 patients, two other studies
have been published.16,17 Thelen et al. described their
single-institution experience in 31 patients who underwent
liver resection for RCC metastases with an overall 5-year
survival of 38%.17 Adam et al. described a series of 1452
patients with noncolorectal, nonneuroendocrine hepatic
metastases, of whom 85 had a primary RCC.16 Median
overall survival was 36 months, with a 5-year survival rate
of 38%.
The reported survival rates in the present study are
superior to the results of older series reviewed by Alioa
et al., and comparable to the recently published series from
Adam et al. and Thelen et al.9,16,17 The improved survival
rates in time could well be explained by better patient
selection, surgical technique, and perioperative care.
Advancements in imaging technology resulting in more
adequate staging, and better appreciation of tumor and
patient characteristics that influence prognosis have prob-
ably contributed to the improved patient selection.
Technical improvements in liver surgery during the past
decades and improvement of perioperative care have
resulted in a safer approach to both minor and major
resections.
Prognostic factors predicting long-term survival after
resection of RCCLM as described in previous series
included male sex, a maximum metastasis diameter
of B 5 cm, primary tumor localization in the left kidney,
disease-free interval of [24 months, and tumor-negative
resection margins.17 The aim of determining such prog-
nostic factors is to establish selection criteria for resection.
In our series, only metachronous metastases and radical
resection had a positive impact on overall survival in uni-
variate analysis. Surprisingly, extrahepatic disease had no
statistically significant impact on survival, with a trend
toward improved survival, although patient numbers are
small. This finding is in agreement with data from Alioa
et al.9 We assume that these patients have only slowly
progressive disease with relatively long disease-free inter-
vals between each distant metastasis. Such patients with
indolent biological behavior of RCC make them ideal
candidates for sequential metastasectomies. Therefore,
selection bias is probably the most important explanation
for this contradictory finding.
We involved all centers performing liver surgery in the
Netherlands. Furthermore, we did a search in the nation-
wide histopathology database, PALGA, in which all data
on resection specimens in the Netherlands are archived. In
this manner, we believe that we reliably retrieved data from
all patients who underwent surgical treatment for hepatic
metastases from RCC in the last 19 years in the Nether-
lands. This fact addresses another interesting point of this
study. From data of the Dutch cancer registry, we know
that 30,000 patients were diagnosed with RCC in the study
period.1 On the basis of the approximately 10 to 20% of
patients with RCC who ultimately developed liver metas-
tases, we can estimate the total number of patients with
RCCLM during this time period in the Netherlands.18–21 In
the last 19 years, approximately 3000–6000 patients (10 to
20% of 29,627) had hepatic metastases due to RCC. In this
particular time period, we identified 33 patients who where
surgically treated, which indicates that approximately 0.5
to 1% of the patients underwent surgical intervention. This
emphasizes once more the remarkably small proportion of
these patients who were treated surgically. The question
remains whether it is only this small proportion of patients
having an indication for surgical treatment, or whether
some patients are not referred by urologists or medical
oncologists for treatment, not being aware of the potential
impact on survival.
We realize the limitations of this study. Data were
obtained from a complete but relatively small group of
patients, limiting analysis on prognostic factors because of
wide confidence intervals and hampering adequate multi-
variate analysis. Data were retrieved over a long study
period (19 years), during which many novel techniques in
imaging, perioperative care, and liver surgery were intro-
duced, as described above. Finally, data were retrieved
from 14 hospitals in a retrospective way, with its inherent
methodological drawbacks. Hence, care must be taken in
drawing strong conclusions from the available data. On the
other hand, the relatively good survival rates, despite a
large heterogeneity in selection criteria of the different
hospitals, together with improvements in liver surgery in
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the last decade, suggest that even better survival rates could
be reached after adequate patient selection.
The survival rates presented in this study and the results
of previous studies compare well with the results of hepatic
resection for colorectal metastases.9,16,17 Likewise, these
survival rates are also certainly not inferior to results after
resection of pulmonary metastases in patients with RCC.
The outcomes of surgery on RCC metastases to the lungs
have been well investigated. Several relatively large series,
although retrospective and nonrandomized, emphasize a
survival benefit, and the possibility of long-term survival
(up to 37% 5-year survival rate) after radical resection in
selected patients with relatively few complications.7,22,23
An aggressive surgical approach to these pulmonary
metastases, in which a radical resection can be achieved, is
currently considered as the appropriate treatment. The
future will tell whether surgical treatment for RCCLM will
achieve the same status as in treatment of RCC lung
metastases. Although molecularly targeted therapies have
resulted in marked survival benefit in metastatic RCC, they
do not provide the possibility of long-term survival. The
results of this study, and of comparable reports in literature,
presume a wider indication for liver resection in patients
with RCC, and deny the suggestion that patients with
RCCLM cannot be cured. Future research should also
further define the role of molecularly targeted therapy in
possible (neo)adjuvant therapies.
In conclusion, surgical treatment of hepatic metastases
from RCC is only performed in approximately 1% of
patients. Data from this study, in accordance with data
from almost 150 patients reported in the literature, suggest
that surgical treatment can provide favorable survival rates,
with a 5-year survival of 43%. The present data on survival
rates after surgery, combined with the unavailability of
effective systemic therapies, justify an aggressive surgical
approach in patients with hepatic metastases from RCC
when a margin-negative resection can be obtained.
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APPENDIX
Collaborators of the Dutch Study Group for Liver Surgery
includes K. P. de Jong, University Medical Center Gron-
ingen (UMCG), Groningen; A. M. Rijken, Amphia
Hospital, Breda; M. P. van den Tol, VU Medical Centre,
Amsterdam; R. A. Tollenaar, Leiden University Medical
Center, Leiden; J. R. van der Sijp, Medisch Centrum
Haaglanden, the Hague; E. J. Hesselink, Gelre Ziekenhui-
zen, Apeldoorn; R. M. van Dam, Maastricht University
Medical Center; J. M. Klaase, Medisch Spectrum Twente,
Enschede; W. Vening, Ma´xima Medical Center, Veldho-
ven; J. A. Van Kollenburg, Maasland Hospital, Sittard.
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